Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab

Table 1 Mean VA at baseline, 3 and 12 months following ranibizumab in CRVO patients categorised by pre-treatment clinical features

Pre-treatment clinical features			Mean VA ± SD (ETDRS letters)
		N (%)	Pre-Treatment	3 Months	12 Months
Base line VA (ETDRS letters)	> 59	14 (27%)	64.6 ± 6.0	64.1 ± 18.5	54.8 ± 26.3
	40–59	23 (44%)	49.8 ± 5.3	57.4 ± 17.0	45.2 ± 30.5
	20–39	6 (12%)	32.8 ± 6.6	36.3 ± 20.4	30.8 ± 18.5
	0–19	9 (17%)	0.6 ± 1.7	28.0 ± 31.4	21.2 ± 31.6
Age (years)	≥75	26 (50%)	40.3 ± 24.3	40.0 ± 24.5	24.7 ± 27.8
Age (years)	< 75	26 (50%)	46.3 ± 20.5	63.3 ± 18.1	59.3 ± 21.8
CWS	Yes	26 (58%)	38.0 ± 25.5	40.8 ± 26.1	31.3 ± 30.4
CWS	No	19 (42%)	48.2 ± 20.2	61.5 ± 17.1	49.6 ± 24.9
Haemorrhages	Multiple Deep Dark	29 (58%)	37.9 ± 25.7	45.8 ± 26.6	36.8 ± 30.7
	Few Scattered	19 (38%)	47.6 ± 19.4	53.0 ± 21.0	42.8 ± 28.1
	None	2 (4%)	60.0 ± 21.2	72.5 ± 17.7	27.5 ± 38.9
Foveal Detachment	Yes	28 (62%)	46.0 ± 22.9	48.4 ± 24.9	40.6 ± 28.5
Foveal Detachment	No	17 (38%)	38.2 ± 22.8	53.8 ± 21.7	37.4 ± 30.3

VA Visual acuity, SD Standard deviation, ETDRS Early Treatment Diabetic Retinopathy Study, N number of eyes, CWS cotton wool spots

ISSN: 1471-2415